Highlight
This large retrospective multicenter study of 1047 AL amyloidosis patients undergoing autologous stem cell transplantation (ASCT) from 2010 to 2020 reveals significantly reduced early mortality (3.0% at day 100), high rates of hematologic response post-transplantation (75.4%), and a median overall survival of 6.3 years. Key prognostic factors impacting survival include age, bone marrow plasma cell burden, disease biomarkers, and conditioning regimen intensity. ASCT continues to serve as an effective consolidative strategy in carefully selected patients despite evolving therapeutic landscapes.
